EXHIBIT 99.1 Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • 2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance • ZYNRELEF® achieved quarterly record of$5.6 million in Q4 Net Product Sales • Ended 2023 with cash and cash equivalents of $80.4 million • Announced partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts on January 7, 2024 • Received FDA approval for ex ...